HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion
Science Advances · 2025
DOI: 10.1126/sciadv.ady1289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Jenny C Pessa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland. Hauptthemen laut MEDLINE: Breast Neoplasms, Heat-Shock Proteins, Carcinoma, Intraductal, Noninfiltrating, Transcription Factors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Breast cancer is hallmarked by phenotypic transitions enabling abnormal cell proliferation and invasion. The stress-protective transcription factor heat shock factor 2 (HSF2) is associated with cancer, but its function in breast carcinogenesis remains poorly understood. Analysis of human breast tumor samples and mouse in vivo xenografts uncovered that HSF2 expression and activity undergo dynamic changes as a function of tumor progression. HSF2 expression, nuclear localization, and coexpression with the proliferation marker Ki67 are increased in ductal carcinoma in situ (DCIS), suggesting that HSF2 designates hyperplastic cells underlying tumor expansion. In mouse xenografts, HSF2 localization switches from nuclear to cytoplasmic upon DCIS-to-invasive transition. Using cell-based models, we identify canonical transforming growth factor–β (TGF-β) signaling as the molecular mechanism regulating HSF2. TGF-β–mediated down-regulation of HSF2 allowed acquisition of an invasive cell phenotype, which was counteracted by ectopic HSF2. Together, we propose that HSF2 acts as a stage-specific switch between proliferation and invasion in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
- Institute of Biomedicine, University of Turku, Turku, Finland.
- Western Finnish Cancer Center (FICAN West), University of Turku and Turku University Hospital, Turku, Finland.
- InFLAMES Research Flagship Center, University of Turku and Åbo Akademi University, Turku, Finland.
- University of Turku and Turku University Hospital, Turku, Finland.
ORCID-Profile: Jenny C Pessa, Oona Paavolainen, Hendrik S E Hästbacka, Mikael C Puustinen, Alejandro J Da Silva, Sandra Pihlström, Pia Boström, Pauliina Hartiala, Emilia Peuhu, Jenny Joutsen, Lea Sistonen
Zitieren
APA
Pessa, J. C., Paavolainen, O., Hästbacka, H. S. E., Puustinen, M. C., Da Silva, A. J., Pihlström, S., Gramolelli, S., Boström, P., Hartiala, P., Peuhu, E., Joutsen, J., & Sistonen, L. (2025). HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion. Science Advances. https://doi.org/10.1126/sciadv.ady1289
Vancouver
Pessa JC, Paavolainen O, Hästbacka HSE, Puustinen MC, Da Silva AJ, Pihlström S, et al. HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion. Science Advances. 2025. doi:10.1126/sciadv.ady1289
BibTeX
@article{Pessa2025,
author = {Pessa, Jenny C and Paavolainen, Oona and Hästbacka, Hendrik S E and Puustinen, Mikael C and Da Silva, Alejandro J and Pihlström, Sandra and Gramolelli, Silvia and Boström, Pia and Hartiala, Pauliina and Peuhu, Emilia and Joutsen, Jenny and Sistonen, Lea},
title = {HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ady1289}
}
EUVIMED